Search results
David Braun, MD, PhD, on Biomarkers in Renal Cell Carcinoma
MedPage Today· 2 days agoFor patients with metastatic renal cell carcinoma (RCC), there are as yet no reliable biomarkers to...
The Key to Finding Predictive Biomarkers in Metastatic Renal Cell Carcinoma?
MedPage Today· 2 days agoIdentification of clinically meaningful, reproducible, and widely available prognostic and, more...
Olympian Maia Shibutani 'Doing Well' After Past Kidney Tumor, Reveals 2024 Olympic Plans (Exclusive)
People via Yahoo Sports· 11 hours ago“I got my pathology report back — the tumor that was successfully removed on Saturday was...
BMS Opdivo and Yervoy combo misses primary endpoint in Phase III NSCLC trial
Clinical Trials Arena via Yahoo Finance· 2 days agoOpdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor. It has been approved to treat a...
HCC Screening of At-Risk Adults Improves Detection, Survival
Medscape· 12 hours agoHepatocellular carcinoma screening was associated with earlier detection and improved survival, even...
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
Zacks via Yahoo Finance· 5 days agoIovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for...
HUTCHMED begins trial of combination therapy for pancreatic ductal adenocarcinoma
Clinical Trials Arena via Yahoo Finance· 1 day agoIn December last year, Hutchmed finished enrolling subjects in a Phase II/III clinical trial of...
HUTCHMED (NASDAQ:HCM) Stock Rating Lowered by StockNews.com
ETF DAILY NEWS· 15 hours agoHUTCHMED (NASDAQ:HCM – Get Free Report) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday ...
Leads Biolabs is Proud to Announce its Participation in the 2024 ASCO Annual Meeting with One Oral...
FOX 4 Kansas City· 3 days agoThe 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from...
Wedbush Boosts Janux Therapeutics (NASDAQ:JANX) Price Target to $74.00
ETF DAILY NEWS· 4 days agoJanux Therapeutics (NASDAQ:JANX – Free Report) had its target price increased by Wedbush from $53.00 to $74.00 in a research note published on Wednesday morning, Marketbeat reports. The brokerage ...